Shri Balaji Valve's customer concentration jumps to 60-65% without explanation
The company also downgraded its new facility from 'initiated capex' to 'brainstorming' – two material reversals that cloud an otherwise solid growth story.
What's new
- FY26 revenue ₹96.81 cr, up 19.5% YoY; EBITDA ₹15.70 cr, up 23.57% YoY.
- H2 revenue grew 34.1% over H1, suggesting capacity utilisation inflection.
- Top 5 customers now account for 60-65% of revenue, up from ~35% in Jan.
- New facility plan rolled back from initiated capex to brainstorming stage.
Themes from the call
Demand
Revenue acceleration in H2 and order book from 14 countries indicate strong demand; oil & gas remains 80-85% of sales, with pharma and defense pilots underway.
Margins
EBITDA margin at ~16% is sustainable but management sees no near-term improvement; raw material and tariff costs are fully pass-through.
Capital allocation
FY26 capex included 5-axis and CNC machines from IPO proceeds; FY27 plans 4-5 more machines, but the new facility remains undefined.
Guidance watch
- Peak revenue capacity of ₹140-150 cr at current facilities – no timeline to reach.
- Target 50-50 domestic-export mix in 5 years, from current 73-27.
- Pilot revenue from defense and pharma expected in next fiscal year.
Risk flags
- Unexplained jump in top-5 customer concentration from 35% to 60-65% raises counterparty risk questions.
- New facility development downgraded to 'brainstorming' from 'initiated capex' – execution ambiguity.
- EBITDA margin guidance of 'sustainable' but no improvement expected implies operating leverage is not materialising yet.
Key quotes
-
"So, top 10 is 65, so top 5, maybe you can... I'll calculate this, but somewhere around 35% is from our top 5 customers."
— Shri Balaji Valve management, Jan 2026 call -
"The top five customers together account for approximately 60-65% of the revenue share."
— Shri Balaji Valve management, Jun 2026 call
The brief
Shri Balaji Valve delivered a solid FY26: revenue of ₹96.81 crore, up 19.5%, and EBITDA up 23.57%. H2 revenue was 34.1% higher than H1, suggesting capacity utilisation is finally kicking in. The company's integrated forging-to-finish model, PED/NORSOK certifications, and repeat-customer base all remain strong narrative assets. But two unexplained pivots demand investor attention. Customer concentration for the top five jumped from roughly 35% to 60-65%, with no explanation. The new facility that was 'initiated' in January is now just 'brainstorming'. The customer concentration shift, if it reflects a large new order, should be positive – but without a bridge, it raises counterparty risk. The facility rollback suggests either capital allocation caution or execution snags. Management's tone on the rest is cautiously optimistic: peak capacity of ₹140-150 crore, a 50-50 export target, and pharma/defence pilots. But the inconsistencies take the shine off. Until the why is offered, these are open questions.
Solid growth, two unexplained pivots – investors need a why before underwriting the story.